# Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030)

> **NCT02661126** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 16 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** MK-3682B

## Key facts

- **NCT ID:** NCT02661126
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-19
- **Primary completion:** 2016-08-26
- **Final completion:** 2016-08-26
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02661126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02661126, "Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT02661126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*